
Please note that any information that you supply is protected by our Privacy Policy. Access to all documents and request for further information are available to all users at no cost. In order to provide you with this free service, Decision News Media does share your information with companies that have content on this site. When you access a document or request further information from this site, your information may be shared with the owners of that document or information.
Almac offers an unparalleled range of integrated services from research, through development to delivery of finished product.
Almac, a privately owned organisation employs over 2,200 dedicated professionals. It has extensive facilities in the UK and US.
Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide, including all the market leaders, use our services.
Research
• Comprehensive genomic and bioinformatics services
• Cancer genomics contract research
• Route design & synthesis of APIs (including potent, peptide & chiral compounds)
• Comprehensive solid state services
• Rapid approach to First in Man
• Synthesis and formulation of labelled compounds
• Comprehensive analytical and stability testing services
Development
Pharmaceutical:
• Formulation, Process optimisation & analytical development
Clinical trials:
• Clinical manufacture, blinding, packaging & randomised labelling
• Technology solutions including IVR/Web Based services, EDC & ePRO
• EU import testing, QP release & global distribution (including cold chain) for clinical product
Commercialisation
• Commercial scale manufacture of intermediates and APIs
• Commercial scale manufacture of solid, oral dosage forms
• Primary / secondary packaging and labelling
• EU import testing, QP release and global distribution (including cold chain) for commercial product